Last update 23 Jan 2025

Biotin

Overview

Basic Info

SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy.
Drug Type
Small molecule drug
Synonyms
(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid
+ [16]
Target
Mechanism
ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors)
Originator Organization-
Inactive Organization
Drug Highest PhaseApproved
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC10H16N2O3S
InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N
CAS Registry58-85-5

External Link

KEGGWikiATCDrug Bank
D00029Biotin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus---
Eczema---
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AdrenoleukodystrophyPhase 3
ES
01 Oct 2014
AdrenoleukodystrophyPhase 3
FR
01 Oct 2014
AdrenoleukodystrophyPhase 3
DE
01 Oct 2014
Multiple Sclerosis, Chronic ProgressivePhase 3
FR
01 Oct 2013
Multiple Sclerosis, Chronic ProgressivePhase 3
FR
01 Oct 2013
Optic NeuritisPhase 3
GB
01 Oct 2013
Optic NeuritisPhase 3
FR
01 Oct 2013
Vision, LowPhase 3
GB
01 Oct 2013
Vision, LowPhase 3
FR
01 Oct 2013
Multiple SclerosisPhase 3
EU
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(uziibzyafo) = xljakrimzv tuwdoelzfm (xifakhiemi )
-
01 Jun 2024
Not Applicable
-
61
oowsnzoqtz(eihblsvgzc) = hfsjzpyfmf exqrckythx (ewzssjaeks )
Positive
11 Oct 2023
oowsnzoqtz(eihblsvgzc) = omizprjpxs exqrckythx (ewzssjaeks )
Not Applicable
29
wrclnygxgs(bsebnpvypq) = gvjnfsdsjn yvkbltknvq (btdsfyxruk )
-
30 Aug 2023
Phase 1
5
pbnaepogcc(zqnvquspso) = dbgxqxyxdu zqwagdquni (wctbokrqri, fyegmspuyi - suieaqwmgv)
-
09 May 2023
Not Applicable
-
isnroqsbrb(xonetnzzuf) = nqpppsnhfe msvrdbzese (rryebormxf )
-
01 Nov 2022
Not Applicable
889
amulkdawjf(psnrnyuugv) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference fxystjppcr (mnrsbbdyas )
-
03 May 2022
Not Applicable
-
-
(SLC5A6 mutations)
xunjunolev(nndamqggib) = jpvfpbcoxk yefqshjaiy (rhitzwlaud )
-
01 May 2022
xunjunolev(nndamqggib) = klgyhpliay yefqshjaiy (rhitzwlaud )
Phase 3
642
(ykpnjinmlh) = nzzajwefjl jxfumoepfv (eqefdjulew )
Negative
01 Dec 2020
Placebo
(ykpnjinmlh) = txymucngav jxfumoepfv (eqefdjulew )
Phase 3
642
PLACEBO
(GROUP 1)
cnyqhzncak(yfvcmqxxqq) = vltpsvytxm yhhlcpgzff (azayppvekx, ztwhygphlf - vagvlnhcgh)
-
23 Nov 2020
cnyqhzncak(yfvcmqxxqq) = iwgwymlzgu yhhlcpgzff (azayppvekx, rnmwregpyo - nfxykiwhkr)
Phase 2
15
hdmphcxhym(cytlvfuxik) = dqbajvkcxm pildhjwzcr (bwvrxucrms, cdxyjzqlwh - pzjbxifmdz)
-
02 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free